THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED "WARNING" ON THE COVER OF THIS DOCUMENT.

IMPORTANT

If you are in any doubt about any of the contents of this Document, you should obtain independent professional advice.

Guangdong Rong Tai Pharmaceutical Co., Ltd.
廣東融泰藥業股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

[REDACTED]

Number of [REDACTED] under the [REDACTED]	**:**	**[REDACTED] H Shares (subject to the [REDACTED])**
Number of [REDACTED]	**:**	**[REDACTED] H Shares (subject to [REDACTED])**
Number of [REDACTED]	**:**	**[REDACTED] H Shares (subject to [REDACTED] and the [REDACTED])**
Maximum [REDACTED]	**:**	**HK$[REDACTED] per H Share (payable in full in Hong Kong SAR dollars on application plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565% and subject to refund)**
Nominal value	**:**	**RMB[0.1] per H Share**
[REDACTED]	**:**	**[REDACTED]**

***Sole Sponsor,* [REDACTED]**

CITIC SECURITIES

[REDACTED]

The **[REDACTED]** is expected to be fixed by agreement between the **[REDACTED]** (for themselves and on behalf of the **[REDACTED]**) and our Company on the **[REDACTED]** or such later date as may be agreed by the **[REDACTED]** (for themselves and on behalf of the **[REDACTED]** and our Company but in any event no later than 12:00 noon on **[REDACTED]**. The **[REDACTED]** will be not more than **[REDACTED]** per H Share and is currently expected to be not less than **[REDACTED]** per H Share. Applicants for **[REDACTED]** may be required to pay, on application (subject to application channels), the Maximum **[REDACTED]** of **[REDACTED]** per H Share together with brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, subject to refund if the **[REDACTED]** should be less than **[REDACTED]** per H Share. If, for any reason, the **[REDACTED]** is not agreed between the **[REDACTED]** (for themselves and on behalf of the **[REDACTED]**) and our Company at or before 12:00 noon on **[REDACTED]**, the **[REDACTED]** (including the **[REDACTED]**) will not proceed and will lapse.

The **[REDACTED]** (for themselves and on behalf of the **[REDACTED]**) may, with our consent, reduce the number of **[REDACTED]** being **[REDACTED]** under the **[REDACTED]** and/or the indicative **[REDACTED]** range below as stated in this Document at any time on or prior to the morning of the last day for lodging applications under the **[REDACTED]** and the **[REDACTED]** will be canceled and relaunched at the revised number of **[REDACTED]** and/or the revised **[REDACTED]** range, as soon as practicable following the decision to make such reduction, and in any event not later than the morning of the last day for lodging applications under the **[REDACTED]**. In such a case, an announcement will be published on the websites of our Company at **https://www.rongtaipharm.com/** and the Stock Exchange at **www.hkexnews.hk** not later than the morning of the day which is the last day for lodging applications under the **[REDACTED]**. Details of the arrangement will then be announced by us as soon as practicable. For further information, please refer to the sections headed "Structure of the **[REDACTED]**" and "How to Apply for the **[REDACTED]**" in this Document.

The obligations of the **[REDACTED]** under the **[REDACTED]** are subject to termination by the **[REDACTED]** (for themselves and on behalf of the **[REDACTED]**) if certain grounds arise prior to [8:00 a.m.] on the **[REDACTED]**. Further details of such circumstances are set out in "**[REDACTED]**".

The **[REDACTED]** have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and may not be **[REDACTED]**, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The **[REDACTED]** are being **[REDACTED]** and sold outside the United States in offshore transactions in accordance with Regulation S.

ATTENTION

We have adopted a fully electronic application process for the **[REDACTED]**. We will not provide printed copies of this Document to the public in relation to the **[REDACTED]**.

This Document is available at the websites of our Company at **https://www.rongtaipharm.com/** and the Stock Exchange at **www.hkexnews.hk**. If you require a printed copy of this Document, you may download and print from the website addresses above.

IMPORTANT

[REDACTED]

IMPORTANT

[REDACTED]